Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

BJU International

Volumn 107, Issue 12, 2011, Pages 1943-1947

  Zhao, Chen ^a   Kim, Suhn Hee ^a   Lee, Sung Won ^b   Jeon, Ju Hong ^c   Kang, Kyung Ku ^d   Choi, Sung Beom ^a   Park, Jong Kwan ^a  

^a Chonbuk National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Dong A Pharmaceutical Company   (South Korea)

Author keywords

lower urinary tract symptoms; phosphodiesterase type 5 inhibitors; sexual function; tadalafil; udenafil

Indexed keywords

CYCLIC AMP; CYCLIC GMP; PHOSPHODIESTERASE V; TADALAFIL; UDENAFIL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TISSUE LEVEL; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION;

AGED; CARBOLINES; ERECTILE DYSFUNCTION; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79957849170     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09759.x     Document Type: Article

References (28)

1. Garraway WM, Collins GN, Lee RJ,. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB,. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61 (Pubitemid 24046934)
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9 (Pubitemid 14026148)
4. Laborde EE, McVary KT,. Medical management of lower urinary tract symptoms. Rev Urol 2009; 11 (Suppl. 1): S19-25
5. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U,. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-11 (Pubitemid 32175951)
6. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM,. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277-84 (Pubitemid 29154831)
7. Burnett AL, Maguire MP, Chamness SL, et al,. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995; 45: 435-9
8. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M,. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008; 26: 603-9
9. Baltaci S, Orhan D, Gogus C, Turkolmez K, Tulunay O, Gogus O,. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 2001; 88: 100-3
10. Uckert S, Kuthe A, Jonas U, Stief CG,. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90 (Pubitemid 33065340)
11. Khan MA, Thompson CS, Dashwood MR, et al,. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr Vasc Pharmacol 2003; 1: 27-31
12. Andersson KE, Chapple CR, Hofner K,. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol 2002; 19: 436-42
13. Kaplan SA, Gonzalez RR,. Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 2007; 9: 73-7
14. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L,. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-34
15. Roumeguère T, Zouaoui Boudjeltia K, Hauzeur C, et al,. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU Int 2009; 104: 511-7
16. Park JK, Cui Y, Kim HJ, Oh HK, Koh GY, Cho KW,. Activation of nitric oxide-cyclic guanosine monophosphate signaling in kidney by extracorporeal shock wave therapy. J Urol 2003; 170: 2459-62 (Pubitemid 37414034)
17. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L,. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010; 105: 502-7
18. Giuliano FA, Lamb J, Crossland A, Haughie S, Ellis P, Tamimi NAM,. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int 2010; 106: 666-73
19. Köhler TS, McVary KT,. The Relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009; 55: 38-48
20. Hotston M, Shukla N, Bloor J, Persad R, Jeremy JY,. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1331-2 (Pubitemid 44721256)
21. Uckert S, Sormes M, Kedia G, et al,. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526-30 (Pubitemid 351374723)
22. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ,. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998; 82 (Suppl. 1): 26-33
23. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P,. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259-63 (Pubitemid 44721238)
24. Mulhall JP, Guhring P, Parker M, Hopps C,. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-7
25. Kaplan SA, Gonzalez RR, Te AE,. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717-23 (Pubitemid 46634750)
26. McVary KT, Roehrborn CG, Kaminetsky JC, et al,. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7 (Pubitemid 46435965)
27. Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG,. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 1997; 15: 32-5 (Pubitemid 127769833)
28. Francis SH, Corbin JD,. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. Urol Clin North Am 2005; 32: 419-29 (Pubitemid 41607530)